The research will leverage the MolecularBreeding technology platform that offers new approach in developing vaccines targeting different HIV-1 strains.
Altravax chief scientific officer Dr. Robert Whalen said the grants will support the company’s plan to develop vaccines capable of stimulating the immune system.
"The current lack of viable vaccine candidates limits the ability of biotechnology companies to invest in HIV vaccine research with their own funds," Dr. Whalen added.
The company obtained exclusive rights to the technology platform from Maxygen in January 2010 for the development of vaccines against infectious diseases.